Cargando…

PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients

Objective: PB-119, a PEGylated exenatide injection, is a once-weekly glucagon-like peptide-1 receptor agonist. In the present study, we aimed to evaluate the effects of PB-119 on insulin resistance and beta-cell function in Chinese patients with type 2 diabetes mellitus (T2DM) to uncover its antidia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xu, Song, Ling, Zhang, Yuanhui, Li, Haiyan, Cui, Cheng, Liu, Dongyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539604/ https://www.ncbi.nlm.nih.gov/pubmed/37781697 http://dx.doi.org/10.3389/fphar.2023.1088670

Ejemplares similares

Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
por: Ji, Linong, et al.
Publicado: (2021)

Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
por: Ji, Linong, et al.
Publicado: (2021)

$\beta$ and $\gamma$-spectroscopy study of $^{119}$Pd and $^{119}$Ag
por: Kurpeta, J, et al.
Publicado: (2022)

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)

Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022)

Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide
por: Zhang, Aihong, et al.
Publicado: (2020)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable‐drug‐naïve elderly or renal impaired patients with type 2 diabetes in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

From Synthesis to Characterization of Site-Selective PEGylated Proteins
por: Belén, Lisandra Herrera, et al.
Publicado: (2019)

The Alleviation of LPS-Induced Murine Acute Lung Injury by GSH-Mediated PEGylated Artesunate Prodrugs
por: Hao, Dan-Li, et al.
Publicado: (2022)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats
por: Klotsman, Michael, et al.
Publicado: (2021)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
por: Du, Xuan, et al.
Publicado: (2018)

Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug
por: DONG, Xinrui, et al.
Publicado: (2017)

Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate
por: Zhang, Baojie, et al.
Publicado: (2014)

Synthesis and Characterization of Poly (β-amino Ester) and Applied PEGylated and Non-PEGylated Poly (β-amino ester)/Plasmid DNA Nanoparticles for Efficient Gene Delivery
por: Iqbal, Sajid, et al.
Publicado: (2022)

$^{119}$Sn Mössbauer study of the implantation behaviour of $^{119}$In, $^{119}$Sn, $^{119m}$Sn, $^{119}$Sb and $^{119m}$Te ions in SiC
por: Petersen, J W, et al.
Publicado: (1985)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

In Vivo Toxicity Evaluation of PEGylated CuInS(2)/ZnS Quantum Dots in BALB/c Mice
por: Zou, Wenyi, et al.
Publicado: (2019)

Folate-Targeted PEGylated Magnetoliposomes for Hyperthermia-Mediated Controlled Release of Doxorubicin
por: Cintra, Emílio R., et al.
Publicado: (2022)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
por: Zhuang, Wei, et al.
Publicado: (2022)

Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
por: Ko, Jung-Woo, et al.
Publicado: (2020)

The decay of $]^{119}$Cd and $\^{119}$In isomers
por: Scheidemann, O, et al.
Publicado: (1976)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA
por: Ge, Xuemei, et al.
Publicado: (2021)

Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model
por: Yang, Jianling, et al.
Publicado: (2020)

FRI617 Targeting Unc119b For Insulin Sensitization
por: Mittal, Ayushi, et al.
Publicado: (2023)

Co-Therapy of Pegylated G-CSF and Ghrelin for Enhancing Survival After Exposure to Lethal Radiation
por: Kiang, Juliann G., et al.
Publicado: (2021)

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
por: Koska, Juraj, et al.
Publicado: (2015)

Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models
por: Demkes, Evelyne J., et al.
Publicado: (2021)

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways
por: Yao, Xueting, et al.
Publicado: (2021)

Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues
por: Mu, Wan, et al.
Publicado: (2019)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Diabetes Mellitus and Alzheimer’s Disease: The Protection of Epigallocatechin-3-gallate in Streptozotocin Injection-Induced Models
por: Jia, Jin-Jing, et al.
Publicado: (2017)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

The Antioxidant Properties of Mushroom Polysaccharides can Potentially Mitigate Oxidative Stress, Beta-Cell Dysfunction and Insulin Resistance
por: Arunachalam, Karuppusamy, et al.
Publicado: (2022)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i5r0u2uinha4qg2nt0in5fgkm0